The Schulich School of Engineering, in partnership with the Charbonneau Cancer Institute, Alberta Children’s Hospital Research Institute (ACHRI), and Snyder Institute, at the University of Calgary invites national and international applications for a full-time position at the rank of Professor with an anticipated start date of January 1, 2025. The selected candidate will be nominated for a Tier I Canada Research Chair (CRC) in Immunoengineering. Further information about the Canada Research Chairs Program can be found on the Government of Canada’s CRC website (https://www.chairs-chaires.gc.ca/home-accueil-eng.aspx) including eligibility criteria.

The successful candidate will be appointed at the rank of Professor (with tenure) in the Department of Biomedical Engineering and will be a member of the Charbonneau Cancer Institute, ACHRI or Snyder Institute. In alignment with the University of Calgary's Ahead of Tomorrow plan and in support of its strategic academic and research priorities, the successful candidate will actively contribute to research, student/postdoc supervision, undergraduate and graduate teaching as well as curriculum development. The successful candidate is expected to have a leadership role within the Department, School, and University, and will also provide service to the department, faculty, institute, University, and community and contribute to achieving equitable, diverse, inclusive and accessible employment practices and workplaces.

The successful candidate will be expected to establish a strong research program in the area of Immunoengineering, with national and international recognition. They will be expected to attract competitive external funding to support their research activities, and to attract excellent trainees and staff. They will also be expected to teach a range of undergraduate and graduate courses, related to their area of expertise. In alignment with the University of Calgary's strategic vision, and in support of its strategic priorities of leadership, teaching and research integration, the successful applicant will actively contribute to teaching and curriculum development.

The successful candidate will be a senior scholar with an original, creative, innovative, and forward-looking research program, acknowledged by their peers as an international leader in the field. Applicants must have earned a Ph.D. in engineering, life sciences, or equivalent. They must have demonstrated evidence of scholarly impact, research productivity, research funding, transdisciplinary collaboration, and the ability to lead a productive independent research group. The ability to attract, supervise and mentor graduate students is essential. Applicants should also show that they have experience in teaching at the graduate and undergraduate level and contributing to their department/school/community. Applicants should demonstrate potential for synergies with existing researchers and research groups across campus. The successful candidate’s research program will focus on Immunoengineering. This may be accomplished through a number of possible topics and applications: biomimetic materials, immune-oncology, molecular engineering, synthetic biology, cell-based therapies, systems immunology and computational immunoengineering, biomanufacturing or regenerative immunology.

The successful candidate is expected to be or become eligible for registration as a professional engineer with the Association of Professional Engineers and Geoscientists of Alberta (APEGA) (https://www.apega.ca/). If any candidates require further information about this criterion, they are encouraged to contact the Department Head.

The research area exemplifies the University of Calgary’s vision of research that is built around areas of excellence, entrepreneurial thinking, innovation, advanced technology, and strong connections to industry and community.

The Schulich School of Engineering is committed to fostering diversity through cultivating an environment where people with a variety of backgrounds, genders, interests and talents feel welcome and included. In 2016, the Schulich School of Engineering was recognized with the KNOVO Award of Distinction to honour the school’s commitment to diversity and equity.

The new Biomedical Engineering Department, with new teaching labs and renovated research labs, is the home of undergraduate (BSc) and graduate (MEng, MSc, PhD) programs and is an anchor for cross-campus transdisciplinary activities in Biomedical Engineering. Biomedical Engineering activities occur across multiple faculties at the University of Calgary (ucalgary.ca/bme) and involve more than 300 faculty members with current annual research funding exceeding $75M. The university has made significant investments in Biomedical Engineering to date, including the allocation of six Tier 1 and nine Tier 2 Canada Research Chairs. A strong culture of collaboration and cross-disciplinary research excellence is enabled by significant research infrastructure located in multiple centers across campus. The University of Calgary’s transdisciplinary Biomedical Engineering research initiative drives innovations that are saving lives and revolutionizing health care. Biomedical Engineering is led by the Schulich School of Engineering, with the Cumming School of Medicine, and the faculties of Kinesiology, Nursing, Science, and Veterinary Medicine. With collaborative teams focused on human mobility, health monitoring and management including e-health, advanced biomedical imaging, precision bio-diagnostics, regenerative medicine and novel medical technologies, our researchers are transforming health services and quality of life.  

The Arnie Charbonneau Cancer Institute (charbonneau.ucalgary.ca/) is a partnership between the University of Calgary and Alberta Health Services, bringing together scientists and clinicians to integrate research and care cross disciplines – from understanding and preventing cancer, to transforming its detection and treatment, to improving life with and after cancer. In 2023, a generous gift from the Riddell Family, through the Alberta Cancer Foundation, with additional matching funds from the Alberta Children’s Hospital Foundation, enabled the creation of the Riddell Centre for Cancer Immunotherapy (RCCI) at the Arnie Charbonneau Cancer Institute, providing a significant investment into the next phase of cancer immunotherapy research and translation, including novel immunoengineering approaches and the development of a biomanufacturing platform to produce immune cell therapies that meet Health Canada and international regulatory standards. With its multidisciplinary team of oncologists, immunologists, pathologists, translational scientists, virologists, cancer modelers, gene scientists, surgeons, imagers, microbiome scientists, computational biologists, cellular engineers, and proteomics specialists with research interests in adult and pediatric cancers, the RCCI program is a strong collaborative environment that is well positioned to be a leader in immune oncology.

The successful candidate will benefit from a rich ecosystem, which includes world-class scholars, a focus on entrepreneurship and innovation, and an equitable, diverse, and inclusive university community that supports transdisciplinary research, partnerships and collaborations, and education excellence. The Schulich School of Engineering Strategic Plan, Schulich Momentum, identifies four pillars: 1) Indigenous Engagement, Inclusivity and Reconciliation; 2) Fostering a Community through Equity, Diversity, Inclusion and Accessibility; 3) Preparing Tomorrow’s Engineering Changemakers; and 4) Elevating Research and Innovation Impact. The Schulich School of Engineering is a key contributor the University of Calgary Ahead of Tomorrow strategic plan, which emphasizes transdisciplinary scholarship, deeper community integration, and future-focused program delivery. For more information, please visit the Schulich School of Engineering website.